Last reviewed · How we verify
NCT04230343
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
NA trial testing Self-benefit message in Influenza Vaccine in 244 participants. Completed in 25 March 2017.
25 March 2017
Quick facts
| Lead sponsor | SB Istanbul Education and Research Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 244 |
| Start date | 13 November 2016 |
| Primary completion | 25 March 2017 |
| Estimated completion | 25 March 2017 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Self-benefit message
- Other-benefit message
Conditions studied
- Influenza Vaccine — all drugs for Influenza Vaccine →
- Behavioral Intervention — all drugs for Behavioral Intervention →
- Self-benefit — all drugs for Self-benefit →
- Social-benefit — all drugs for Social-benefit →
Sponsor
SB Istanbul Education and Research Hospital
Who can join
Adults 18 to 90, any sex, with Influenza Vaccine or Behavioral Intervention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Limits of the social-benefit motive among high-risk patients: a field experiment on influenza vaccination behaviour.
Isler O, Isler B, Kopsacheilis O, Ferguson E. · · 2020 · cited 24× · PMID 32066407 · DOI 10.1186/s12889-020-8246-3
Verify or expand the search:
- PubMed search for NCT04230343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Influenza Vaccine
Currently open trials in the same condition.
- NCT07421037 — Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older · Phase 1 · active not recruiting
- NCT07421050 — Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older · Phase 1 · active not recruiting
- NCT05518500 — A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults · Phase 4 · recruiting
Other SB Istanbul Education and Research Hospital trials
Trials by the same sponsor.
- NCT07071571 — New Intraoperative Nerve Monitoring Device · NA · not yet recruiting
- NCT06873087 — Changes in PACAP, CGRP, and VIP Levels in Rosacea Patients on Systemic Isotretinoin and Their Association with Erythema · Phase 4 · completed
- NCT03780998 — Effects of Sodium Pentaborat Based Gel on Perianal Benign Diseases · unknown
- NCT04940169 — Anterior Cruciate Ligament Reconstruction Made With Hamstring Tendon And Quadriceps Tendon Autografts · NA · completed
- NCT03051308 — University of Wisconsin Solution Versus New Parathyroid Transport Solution for Parathyroid Allotransplantation · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04230343 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SB Istanbul Education and Research Hospital
- Last refreshed: 18 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04230343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing